Compare HWBK & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HWBK | CNTX |
|---|---|---|
| Founded | 1865 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 253.0M | 283.9M |
| IPO Year | 1996 | 2021 |
| Metric | HWBK | CNTX |
|---|---|---|
| Price | $37.00 | $1.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 3.8K | ★ 691.6K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.49% | N/A |
| EPS Growth | ★ 31.42 | 17.39 |
| EPS | ★ 0.83 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $44.41 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.07 | $0.56 |
| 52 Week High | $37.30 | $3.62 |
| Indicator | HWBK | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 56.67 | 30.22 |
| Support Level | $34.49 | $1.39 |
| Resistance Level | N/A | $1.55 |
| Average True Range (ATR) | 0.86 | 0.22 |
| MACD | 0.02 | -0.11 |
| Stochastic Oscillator | 78.87 | 4.97 |
Hawthorn Bancshares Inc is a financial holding company that, along with its subsidiary bank, provides commercial banking for small and mid sized businesses, including equipment, operating, commercial real estate and SBA loans, and personal banking services such as real estate mortgage lending, installment and consumer loans, certificates of deposit, and checking, savings and money market accounts. It has two segments, banking and wealth management, with the banking segment earning the majority of its revenue and conducting general banking business, offering checking and savings accounts, internet banking, debit cards, certificates of deposit, brokerage services and others. Its primary source of revenue is net interest income derived from lending and deposit taking activities.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.